Are the IRBs prioritizing reviews of submissions?
Last updated: 3.16.2020
Yes. We are doing additional triage of all submissions (except continuing reviews) and prioritizing as follows:
- Initial reviews:
- FDA treatment protocols (HDEs, e-uses)
- COVID studies (see below)
- Potentially therapeutic clinical trials
- Applications with funding approval needs
- Changes of protocol:
- COVID-related changes
- Safety-related changes
- Changes to potentially therapeutic studies
- Funding changes
- Reportable events
- COVID-related reports take priority
If you have urgent review needs not covered above, please contact the following:
- For HS/MR IRBs, please email irbdirector@hsirb.wisc.edu
- For the ED/SBS IRB, please email arrow-help@mailplus.wisc.edu